NCT03256799已完成4 期
An Open Label Study to Investigate the Role of Ivacaftor for the Treatment of Cystic Fibrosis in Combination With Ataluren (PTC124) in Cystic Fibrosis Patients Using Ataluren for Nonsense Mutations
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Lung Function
研究概览
简要总结
The purpose of this study is to explore the combination of Ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation
详细描述
In about 10% of patients with CF, the defect in the gene is known as a stop mutation. This mutation truncates the cystic fibrosis transductive regulator (CFTR) protein production by introducing a premature stop in the messenger RNA (mRNA), this type of mutation is known as a stop mutation. Ataluren is a novel, oral drug that promotes this gene to work effectively and readthrough that premature "stop sign". It is hypothesized that ivacaftor may increase the efficacy of Ataluren by activating a specific protein that may not be functioning properly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial.
- •Age ≥19 years
- •Body weight ≥16 kg
- •Diagnosis of cystic fibrosis and documentation of the presence of a nonsense mutations of the CFTR gene, as determined by historical genotyping
- •Ability to perform a valid, reproducible spirometry with demonstration of a forced expiratory volume in 1second (FEV1) ≥30% of predicted for age, gender, and height.
- •If the subject is sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration
- •Willingness and ability to comply with all study procedures and assessments.
- •Currently receiving Ataluren for nonsense mutations through other clinical trial access.
排除标准
- •Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or re-initiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 2 weeks prior to screening.
- •Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 2 weeks prior to screening.
- •Ongoing immunosuppressive therapy (other than corticosteroids up to 10mg/d equivalent of prednisone)
- •Ongoing warfarin, phenytoin, or tolbutamide therapy.
- •History of solid organ or hematological transplantation.
- •A history of positive hepatitis B surface antigen test, hepatitis C antibody test, or human immunodeficiency
- •Major complications of lung disease (including massive hemoptysis, pneumothorax, or pleural effusion) within 4 weeks prior to screening.
- •Pregnancy or breast-feeding.
- •Current smoker or a smoking history of ≥10 pack-years (number of cigarette packs/day × number of years smoked).
- •Prior or ongoing medical condition (eg, renal failure, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
研究组 & 干预措施
Ivacaftor/Ataluren
Experimental
干预措施: Ivacaftor/Ataluren (Drug)
结局指标
主要结局
Lung Function
时间窗: Baseline through 48 weeks
change in lung function as measured by spirometry
次要结局
未报告次要终点
研究者
Steven M Rowe
Principal Investigator
University of Alabama at Birmingham
研究点 (1)
Loading locations...
相似试验
已完成
4 期
PTC Study to Evaluate Ataluren in Combination With IvacaftorCystic FibrosisNCT03256968University of Alabama at Birmingham1
已完成
2 期
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.NeoplasmsNCT00448136Hoffmann-La Roche83
已完成
3 期
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR MutationCystic FibrosisNCT02725567Vertex Pharmaceuticals Incorporated57
终止
2 期
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR MutationCystic FibrosisNCT00953706Vertex Pharmaceuticals Incorporated140
已完成
3 期
An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing MutationsCystic FibrosisNCT02934698Medical University of South Carolina2